Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 3Unknown 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 1397Neoplasms 1129Prostatic Neoplasms 744Lung Neoplasms 619Colorectal Neoplasms 596Carcinoma, Non-Small-Cell Lung 569Carcinoma, Hepatocellular 413Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 355Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 309Head and Neck Neoplasms 289Neoplasm Metastasis 273Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 253Uterine Cervical Neoplasms 248Recurrence 248Melanoma 242Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 213Sarcoma 207Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 183

Interventions

pyrotinib 1pertuzumab 1disitamab vedotin 1Trastuzumab 1RC48 antibody 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × OTHER × HER2-positive Metastatic Breast Cancer × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT06278870 2024-02-26

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 3 Recruiting
312 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡